Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Recarbrio

Can Cinderella save us?

Conference discusses global targets in fight against antimicrobial resistance

World Health Organization reports show AMR is one of the top ten threats to global health

Can Cinderella save us?

Study finds antibiotic resistant bacteria can migrate from gut to lungs

Eliminating AMR pathogens from the gut microbiome of patients could prevent infections

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

- PMLiVE

Merck to acquire Imago BioSciences in deal worth $1.35bn

The agreement includes lead candidate, bomedemstat, for myeloproliferative neoplasms

- PMLiVE

European MPs call for urgent action against antimicrobial resistance

It is estimated that AMR could lead to as many as ten million deaths each year by 2050

- PMLiVE

World Antimicrobial Awareness Week 2022

Reports from the World Health Organization show that AMR is one of the top ten threats to global health

- PMLiVE

MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children

The decision marks the first new vaccine approved by MHRA in a decade for this indication

- PMLiVE

WHO publishes first-ever fungal priority pathogens list in face of antimicrobial resistance

The list highlights the public health threat presented by fungal infections on a global scale

- PMLiVE

Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial

The study met its primary endpoint of a clinically meaningful improvement in six-minute walk distance

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment

The drug will not be available as a treatment option for men with prostate cancer in England and Wales

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links